MET overexpression as a promising therapeutic target in non-small cell lung cancer with acquired resistance to EGFR TKIs.

e19047 Background: MET amplification is recognized as one of common molecular mechanisms of acquired resistance (AR) to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in advanced non-small-cell lung cancer (NSCLC). The aim of the present study is to investigate the frequency of MET overexpression, the correlated clinicopathologic features and the possible treatments in NSCLC with AR. Methods: Advanced NSCLC patients with AR to EGFR TKIs were detected for MET overexpression by immunohistochemistry (IHC). ≥50% tumor cells with moderate to high intensity staining were defined as MET positive. MET positive patients were recommended to participate a clinical trial if eligible or receive other molecularly targeted therapies. The statuses of EGFR, ALK, KRAS and ROS1 were also tested. Results: From January 2013 to January 2014, 58 advanced NSCLC patients with AR to gefitinib or erlotinib were enrolled prospectively. The frequencies of MET overexpression was 32.8% (19/58), MET overexpressi...